Skip to main content

Table 1 The types of circRNAs in gastric cancer (GC) identified in recent studies

From: Current prevalence status of gastric cancer and recent studies on the roles of circular RNAs and methods used to investigate circular RNAs

CircRNAs

Select reasons

Regulation

Distance from cancerous tissue (cm)

Tissue source

Date (tissue collection)

Fold change

Functions of the studied circRNA

Literature

hsa_circ_0000190

It is down-regulated in GC tissues, and its expression is significantly related to the major clinic pathological factors of patients with GC.

Down-regulated

5

Ningbo Yinzhou People’s Hospital, China

June 2010 to January 2015

–

It is a novel, non-invasive biomarker for the diagnosis of GC.

[40]

circRNA_100269

It is an independent predictor of early recurrence of stage III GC. Its role in cancer progression remains unknown.

Down-regulated

–

Nanfang Hospital of Southern Medical University

December 2012 to May 2015

–

It is negatively correlated with miR-630; both of them comprise a novel pathway that regulates the proliferation of GC cells.

[41]

circLARP4

It is derived from the LARP4 gene locus.

Down-regulated

–

Downloaded from the Cancer Genome Atlas 2015 RNA sequencing database

–

–

It may act as a novel tumour suppressive factor and is a potential biomarker for GC.

[42]

hsa_circ_0014717

The global expression profile of this circRNAs in human GC has not yet been revealed. It is one of the moderately down-regulated circRNAs in microarray screening results.

Down-regulated

5

Affiliated Hospital of Medical School of Ningbo University (China)

February 2011 to February 2016

–

It has the potential to be used as a novel biomarker for the screening of high-risk GC patients.

[43]

hsa_circ_0000026

Its expression was significantly different between the GC and control samples (P = 0.001) in both qPCR and microarray analyses.

Down-regulated

≥5

Affiliated Hospital of Hainan Medical University (Haikou, China)

June 2014 to July 2014

2.8

It can regulate RNA transcription, RNA metabolism, gene expression, and gene silencing, and it also has other biological functions.

[44]

hsa_circ_0000745

It is down-regulated in GC tissues compared to non-tumorous tissues and in plasma samples from patients with GC vs healthy controls.

Down-regulated

–

Hospital Affiliated to Anhui Medical University (China)

January 2016 to January 2017

–

It plays an important role in GC, and its expression level in plasma can be measured in combination with the CEA level.

[45]

circPVT1

It is derived from the PVT1 gene locus and is frequently upregulated in patients with GC.

Up-regulated

–

Fudan University, Shanghai Cancer Center (FUSCC)

December 2007 to December 2010

–

It is a novel proliferative factor and prognostic marker in GC.

[46]

Hsa_circ_002059

It is one of the circRNAs associated with GC according to bioinformatics analysis in two circRNA databases: CircBase and circ2Traits.

Down-regulated

5

Yinzhou People’s Hospital and the Affiliated Hospital of Ningbo University, China

June 2012 to December 2013

–

It may be a potential novel, stable biomarker for the diagnosis of GC.

[47]

hsa_circ_0001895

It may be associated with GC according to the bioinformatics analysis in CircBase database.

Down-regulated

5

Affiliated Hospital of Ningbo University School of Medicine, China

November 2014 to February 2016

–

It may play crucial roles in GC initiation and it is a potential biomarker for prognosis prediction.

[48]

hsa_circ_0000520

It significantly down-regulated based on the microarray findings.

Down-regulated

5

Nanjing Hospital, affiliated with the Nanjing Medical University, China

2015–2016

–

It could serve as a novel biomarker for GC, and it is involved in GC development.

[49]